New wrinkle injection shows promise in early trial
NCT ID NCT04821089
First seen Jun 24, 2026 · Last updated Jul 29, 2026 · Updated 3 times
Summary
This study tests a new injection called IPN10200 for moderate to severe upper facial lines, like frown lines and forehead wrinkles. About 727 adults aged 18 to 65 will receive either the injection or a placebo. The goal is to see if it safely reduces wrinkles better than a dummy treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IPN10200 (a botulinum toxin type A injection)
- What this could lead to
- If it works, this could provide a new option for reducing frown lines, forehead wrinkles, and crow's feet.
- What could go wrong
- This is an early-stage trial, so the treatment may not work better than placebo or existing options. Side effects like bruising, pain, or temporary muscle weakness are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE UPPER FACIAL LINES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aimed S.A.S
Lyon, France
-
CRS Clinical Research Services Berlin GMBH
Berlin, 13353, Germany
-
Clinique de Chirurgie Esthétique Iéna
Paris, France
-
Dermatologische Gemeinschaftspraxis Blankenfelde-Mahlow
Mahlow, Germany
-
Fachbereich Chemie Institut für Biologie und Molekularbiologie Studiengang Kosmetikwissenschaft
Hamburg, Germany
-
Interdisciplinary Study Association
Kassel, State of Berlin, Germany
-
Interdisciplinary Study Association
Berlin, Germany
-
MEDITI - Clinique Del Mar
Antibes, France
-
Privatpraxis Dr. Hilton & Partner
Düsseldorf, Germany
-
ROSENPARK RESEARCH GmbH
Darmstadt, Germany